Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

John Gerich
Department of Medicine, Endocrine/Metabolism Division, University of Rochester School of Medicine, Rochester, NY, USA

Abstract: Postprandial plasma glucose concentrations are an important contributor to glycemic control. There is evidence suggesting that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are antidiabetic agents that predominantly reduce postprandial plasma glucose levels. DPP-4 inhibitors are associated with fewer gastrointestinal side effects than GLP-1 receptor agonists and are administered orally, unlike GLP-1 analogs, which are administered as subcutaneous injections. GLP-1 receptor agonists are somewhat more effective than DPP-4 inhibitors in reducing postprandial plasma glucose and are usually associated with significant weight loss. For these reasons, GLP-1 receptor agonists are generally preferred over DPP-4 inhibitors as part of combination treatment regimens in patients with glycated hemoglobin levels above 8.0%. This article reviews the pathogenesis of postprandial hyperglycemia, the mechanisms by which GLP-1 receptor agonists and DPP-4 inhibitors reduce postprandial plasma glucose concentrations, and the results of recent clinical trials (ie, published 2008 to October 2012) that evaluated the effects of these agents on postprandial plasma glucose levels when evaluated as monotherapy compared with placebo or as add-on therapy to metformin, a sulfonylurea, or insulin. Findings from recent clinical studies suggest that both GLP-1 receptor agonists and DPP-4 inhibitors could become valuable treatment options for optimizing glycemic control in patients unable to achieve glycated hemoglobin goals on basal insulin, with the added benefits of weight loss and a low risk of hypoglycemia.

Keywords: postprandial hyperglycemia, glucagon-like peptide-1, dipeptidyl peptidase-4, type 2 diabetes mellitus

Introduction
Type 2 diabetes is a chronic, progressive disease in which hyperglycemia occurs due to an imbalance between the body’s need for insulin and its ability to produce it. The progressive nature of the disease results from a continuing deterioration in pancreatic β-cell function and development of hyperglycemia.1-3 The first step in the deterioration of glucose homeostasis is the loss of postprandial glycemic control, which is followed by a progression to morning hyperglycemia and eventually to sustained nocturnal hyperglycemia.4-6 Impaired glucose tolerance is considered a prediabetic stage, and it may occur years before elevated fasting plasma glucose (FPG) levels are observed.7 It is defined as 2-hour postprandial plasma glucose (PPG) levels between 140 and 199 mg/dL following a 75 g oral glucose tolerance test.6,8 Postprandial hyperglycemia can be the rate-limiting factor for achieving optimal glycemic control.9
There is also evidence suggesting that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease, stroke, retinopathy, renal failure, and neurologic complications in both diabetic and nondiabetic individuals. One of the proposed mechanisms of diabetic vascular disease is the observed increase in oxidative stress that occurs following consumption of meals that produce a high level of glycemia. This oxidative stress has been shown to induce endothelial dysfunction and increase inflammation, vasoconstriction, and carotid intima-media thickness.

PPG control is important not only for regulating glycemia, but also because reducing postprandial hyperglycemia may mitigate cardiovascular risks. To achieve optimal glycemic control, the consensus statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends a patient-centered approach to incorporate individual factors such as lifestyle, cost, motivation, and need to lose weight. Further, the most recent guidelines from the International Diabetes Federation recognize the importance of PPG control in mitigating cardiovascular risks and include strategies for cardiovascular risk reduction as a major focus of therapy.

Two noninsulin classes of drugs that have shown significant clinical benefits by predominantly reducing PPG excursions and lowering glycated hemoglobin (HbA1c) are glucagon-like peptide-1 (GLP-1) derivatives (eg, the US Food and Drug Administration [FDA]-approved drugs liraglutide, exenatide, and exenatide long-acting release [LAR]; and the investigational drugs albiglutide and lixisenatide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (eg, the FDA-approved sitagliptin, saxagliptin, and linagliptin). The purpose of this paper is to review the pathogenesis of postprandial hyperglycemia, the mechanisms by which GLP-1 receptor agonists and DPP-4 inhibitors reduce PPG concentrations, and the results of recent clinical trials that have evaluated the effects of GLP-1 receptor agonists and DPP-4 inhibitors (the newest class to become available) on PPG levels, specifically as monotherapy versus placebo or as add-on therapy to metformin, a sulfonylurea, or insulin.

Pathogenesis of postprandial hyperglycemia

In nondiabetic individuals, pancreatic β-cells increase the release of insulin in response to food consumption and release a relatively constant level of insulin during the fasting state. After food ingestion, an increase in plasma glucose levels and a release of insulin inhibit glucagon secretion; together, these suppress glucagon release into the circulation by the liver and kidneys and promote glucose uptake in various tissues.

In people with postprandial hyperglycemia, early insulin release after food ingestion is decreased and there is less reduction in glucagon secretion, resulting in inappropriate glucose production in the liver and kidneys and inefficient glucose uptake, and consequently, increased PPG levels. The overall amount of ingested glucose absorbed by the body does not change. Mass action effects of hyperglycemia normalize the absolute amount of PPG taken up by tissues. However, there is decreased tissue glucose clearance and glucose oxidation, with increased nonoxidative glycolysis, glycogen cycling, and glucose uptake in alternative tissues throughout the body. The net result is that more glucose (endogenous + ingested) enters the circulation at a faster rate than the body can remove it, resulting in prolonged elevations of plasma glucose.

Several studies demonstrate that management of PPG is important for achieving glycemic control. Monnier et al assessed the relative importance of postprandial and fasting hyperglycemia on overall glycemic control in 290 patients (139 male/151 female; mean age ± standard deviation 60±1 years) and found that postprandial hyperglycemia was responsible for approximately 70% of day-long hyperglycemia in patients with HbA1c levels below 7.3%, compared with approximately 40% in patients with HbA1c levels of 9.3% or higher. Similarly, Woerle et al found that in 164 patients (90 male/74 female; mean age 62±1 years), over 80% of HbA1c was due to postprandial hyperglycemia in patients with HbA1c levels below 6.2%, whereas only about 40% of HbA1c was due to postprandial hyperglycemia in patients with HbA1c levels >8.9%. In an analysis of 1,699 patients (58% male/42% female; mean age 59±9 years) from six clinical trials in which patients with HbA1c levels >7.0% taking oral therapy received treatment intensification, Riddle et al found that the effect of targeting PPG became more important in patients who were unable to achieve glycemic control after basal insulin therapy. In this study, the relative contribution of PPG to HbA1c was in the range of 76%–80% at baseline but decreased to 31.5%–41% after 24–28 weeks of treatment with basal insulin therapy.

In the early stages of prediabetes and diabetes, the deleterious effects of an imbalance between impaired insulin secretion and insulin resistance are more apparent in the postprandial state than in the fasting state (Figure 1). PPG levels increase earlier and faster than FPG levels because more insulin is needed after meals than in the fasting state in
order to maintain glucose homeostasis. In addition, most PPG metabolism occurs via insulin-sensitive pathways; however, in the fasting state most glucose disposal is not dependent on insulin. Often by the time diabetes is diagnosed based on elevated FPG levels, β-cell function has decreased by approximately 50%.6,26

Hyperglycemia-induced oxidative stress has been proposed as the biological mechanism to explain the putative link between postprandial hyperglycemia and cardiovascular disease.7,13,27–30 (Figure 2).31 Hyperglycemia is associated with an increase in mitochondrial superoxide production, which is accompanied by an increase in the production of nitric oxide resulting from uncoupling of endothelial nitric oxide synthase and inducible nitric oxide synthase.27 Overproduction of superoxide leads to production of other reactive oxygen species, including the strong oxidant peroxynitrite, which causes oxidative damage to DNA.29 Peroxynitrite-induced DNA damage causes activation of the nuclear enzyme poly(adenosine diphosphate-ribose) polymerase, which induces a series of cellular responses that ultimately result in acute vascular endothelial dysfunction.29 Vascular endothelial dysfunction has been recognized as a key step in the early development of cardiovascular disease.28 Endothelial dysfunction results in an impairment of endothelium-dependent vasodilation, as well as an increase in proinflammatory, procoagulatory, and proliferative responses, all of which are associated with the development of atherosclerosis.29

The possible association between PPG control and reduction in adverse cardiovascular outcomes remains controversial. It has been observed that pharmacologic strategies that target PPG to slow the progression of type 2 diabetes have reduced cardiovascular morbidity and mortality. Compared with regular insulin, the fast-acting insulin aspart lowered postprandial hyperglycemia and also preserved flow-mediated vasodilation, which is lowered in the postprandial state in diabetic patients.32 In a study of 175 drug-naïve patients (93 male/82 female; age range 35–70 years) with type 2 diabetes, patients treated with the insulin secretagogue repaglinide experienced a greater regression of carotid intima-media thickness compared with patients treated with glyburide, another secretagogue associated with a lower efficacy in reducing postprandial hyperglycemia.33 In this study, carotid intima-media thickness regression was shown to be associated with changes in postprandial but not fasting hyperglycemia.

However, other pharmacologic agents used to lower PPG showed no significant improvement in cardiovascular outcomes. In contrast with the results found with repaglinide,33 the incidence of cardiovascular events on treatment with another insulin secretagogue, nateglinide (4,645 patients, 2,277 male/2,368 female; mean age 64±7 years) was not significantly different from placebo (4,661 patients, 2,318 male/2,343 female; mean age 64±7 years) in a patient population with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors in the NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) study.34 While nateglinide has been shown to significantly lower PPG compared with placebo,35 post-meal glucose was higher in the nateglinide arm compared with placebo for up to 5 years post follow-up in the NAVIGATOR study.34 In the HEART2D (Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) study, the risk of a first primary cardiovascular event in patients with type 2 diabetes after acute myocardial infarction was not significantly different for patients treated with prandial insulin (557 patients, 356 male/201 female; mean age 61±10 years) compared with basal insulin (558 patients, 350 male/208 female; mean age 61±10 years); this trial was stopped for lack of efficacy.36 The HEART2D study may have been underpowered to detect differences in cardiovascular effects due to a low rate of cardiovascular events in the basal and prandial treatment arms. The study also reported low efficacy with respect to PPG (the predetermined difference of 2.5 mmol/L in postprandial hyperglycemia between treatment groups was not reached [mean difference at the end of the study: 0.8 mmol/L]).37

Thus, prevention of the progression of diabetes and possibly further reduction of the risk of cardiovascular disease by treating postprandial hyperglycemia may not be
straightforward with some agents and may be dependent on the extent of reduction of PPG.

It is important for clinicians to monitor and treat postprandial hyperglycemia in order to achieve optimal glycemic control. In patients who do not achieve their glycemic goals with oral agents that mainly affect fasting hyperglycemia (eg, metformin, sulfonylureas, and thiazolidinediones) and basal insulin, further titration of basal insulin or the addition of prandial insulin may result in unwanted consequences, such as hypoglycemia and weight gain. The addition of other complementary interventions, such as GLP-1 receptor agonists or DPP-4 inhibitors, to basal insulin therapy may improve glycemic control while avoiding the side effects of weight gain and hypoglycemia that may be associated with higher doses of insulin therapy.

Figure 2 Cell mechanism linking impaired glucose utilization in type 2 diabetes and cardiovascular disease. Insulin signal transduction in individuals with normal glucose tolerance (A) and with type 2 diabetes (B). Insulin signaling through IRS-1 is impaired in type 2 diabetes, leading to decreased glucose transport/phosphorylation/metabolism and impaired NOS activation/endothelial function. Insulin resistance in the IRS-1/PI-3 kinase pathway results in compensatory hyperinsulinemia, excessive stimulation of the MAP kinase pathway, and subsequent inflammation, cell proliferation, and atherogenesis.

Abbreviations: IRS-1, insulin-receptor substrate 1; NOS, nitric oxide synthase; PI-3, phosphoinositide 3; MAP, mitogen-activated protein; SHC, Src-homology collagen.
Role of incretins in glycemic regulation

The intestinal incretin hormones GLP-1 and glucose-dependent insulinoceptive polypeptide (GIP) are released during absorption of meals and stimulate pancreatic β-cells to secrete insulin.\(^\text{50,41}\) It is estimated that GLP-1 and GIP are responsible for 50%–70% of postprandial insulin release.\(^\text{42}\) In addition, GLP-1 suppresses inappropriate glucagon secretion by pancreatic α-cells, and at pharmacologic doses, delays gastric emptying by inhibiting gastroduodenal motility. The delay in gastric emptying caused by GLP-1 is associated with an increase in satiety and reduced food intake.\(^\text{40,43,44}\) Both GLP-1 and GIP are rapidly broken down by DPP-4 after secretion.\(^\text{45}\)

In animal models and in some experiments using isolated human islets, GLP-1 has also been shown to stimulate proliferation and differentiation of pancreatic β-cells and to inhibit β-cell apoptosis.\(^\text{46,47}\) Thus, it has been postulated that incretin-based therapies may increase β-cell mass in patients with type 2 diabetes.\(^\text{43}\)

PPG-lowering effects of GLP-1 receptor agonists and DPP-4 inhibitors

Mechanistic and clinical data for the GLP-1 receptor agonists and DPP-4 inhibitors in reducing PPG are discussed herein, with recent clinical trial results summarized in Tables 1–4. Regarding the clinical trial data, searches of the US National Library of Medicine PubMed.gov database were conducted in October 2012 for each of the various agents (approved and investigational), focusing on English-language reports of randomized controlled trials published since 2008 as monotherapy (placebo-controlled trials only) or as add-on therapy to metformin, a sulfonylurea, or insulin therapy (placebo-controlled or active-controlled; of note, trials evaluating their use as initial combination therapy, rather than add-on therapy, are not covered here). The full text of identified articles was reviewed to identify those that reported on PPG outcomes (Tables 1–4). Selected data available in meeting abstract form were also considered.

GLP-1 receptor agonists

Endogenous GLP-1 is impractical as a therapeutic agent for type 2 diabetes because it is rapidly broken down by DPP-4;\(^\text{41}\) however, several synthetic DPP-4-resistant GLP-1 analogs have been developed.\(^\text{40,41,43}\) These GLP-1 receptor agonists have the same actions as endogenous GLP-1.\(^\text{46}\) For patients with type 2 diabetes who have not responded to treatment with monotherapy or combination therapy using sulfonylureas or metformin, GLP-1 receptor agonists may have similar efficacy to that of insulin in lowering HbA\(_1c\) levels, without weight gain or hypoglycemia.\(^\text{49}\)

The 2012 ADA/EASD position statement for the management of hyperglycemia in patients with type 2 diabetes mellitus indicates that GLP-1 agonists may be considered at multiple points throughout treatment.\(^\text{17}\) This is in contrast with the earlier 2009 ADA/EASD consensus algorithm, which indicated that GLP-1 agonists be considered as add-on therapy for patients who fail initial treatment with metformin and lifestyle interventions alone.\(^\text{50,51}\) In the 2012 ADA/EASD position statement,\(^\text{17}\) GLP-1 receptor agonists can be considered as initial drug monotherapy when metformin cannot be used and weight loss is seen as an essential part of therapy, as add-on to metformin after considering starting HbA\(_1c\), and as part of several three-drug or four-drug combinations that exclude DPP-4 inhibitors (eg, combination of metformin and a GLP-1 receptor agonist with a sulfonylurea or thiazolidinedione with or without basal insulin). At all points, the risk of hypoglycemia and other side effects, the importance of weight loss, and costs are considered on an individual basis.

There are currently three GLP-1 analogs, ie, exenatide (Byetta®; Amylin Pharmaceuticals Inc, San Diego, CA, USA),\(^\text{72}\) a long-acting release formulation of exenatide, exenatide LAR (Bydureon®; Amylin Pharmaceuticals Inc, San Diego, CA, USA),\(^\text{53}\) and lixisenatide (Victoza®; Novo Nordisk A/S, Bagsvaerd, Denmark),\(^\text{54}\) that are approved in the US for the treatment of type 2 diabetes.\(^\text{55}\)

Exenatide is a synthetic incretin mimic that has 53% homology with endogenous human GLP-1;\(^\text{11}\) because it is resistant to degradation by DPP-4; however, exenatide has a longer circulating half-life than endogenous GLP-1. Exenatide binds to GLP-1 receptors on pancreatic β-cells and augments glucose-mediated insulin secretion.\(^\text{43,50}\) Cervera et al studied the mechanism of action by which exenatide (12 patients, nine male/three female; mean age 44±2 years) reduces PPG concentration and found that by decreasing endogenous (mostly hepatic) glucose production by approximately 50% and by delaying gastric emptying, exenatide significantly reduces postprandial hyperglycemia.\(^\text{57}\) Approximately one third of the reduction in postprandial hyperglycemia was due to delayed gastric emptying and enhanced splanchnic glucose uptake.\(^\text{57}\) Another one third of the reduction was due to inhibition of glucagon secretion, and one third was due to stimulation of insulin secretion in pancreatic β-cells.\(^\text{57}\)
Table 1 PPG outcomes as monotherapy: placebo-controlled trials published from 2008 to October 2012

| Drug                  | Baseline demographics | Treatments                                                                 | PPG outcome                                                                 |
|-----------------------|-----------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| GLP-1 analogs         |                       |                                                                            |                                                                            |
| Exenatide             | 96                    | 36/60                                                                      | Mean PPG at week 24 decreased to a greater extent with exenatide plus lifestyle modification versus placebo plus lifestyle modification (P<0.0001 for midday meal) | Mean decreases from baseline to week 24 in morning, evening, and daily PPG(E) significant with both doses of exenatide versus placebo (P<0.002); however, no difference between either dose versus placebo for midday PPG(E) |
| Exenatide             | 232                   | 130/102                                                                   |                                                                            |                                                                            |
| Liraglutide           | 18                    | 14/4                                                                       |                                                                            |                                                                            |
| Liraglutide           | 72                    | 63/57                                                                      | Mean decreases in PPG levels at steady-state significant with all three liraglutide doses versus placebo (P<0.001), except for liraglutide 2-step titration and 1-step titration versus placebo (95% CIs -5.38 to -2.35 mmol/L and -6.29 to -3.36 mmol/L, respectively; both P<0.0001) | Mean decreases in PPG levels at steady-state significant with all three liraglutide doses versus placebo (P<0.001), except for liraglutide 2-step titration and 1-step titration versus placebo (95% CIs -5.38 to -2.35 mmol/L and -6.29 to -3.36 mmol/L, respectively; both P<0.0001) |
| Lixisenatide          | 62                    | 63/57                                                                      |                                                                            |                                                                            |
| Saxagliptin           | 56                    | 58/44                                                                      | Mean decreases from baseline to week 12 were significant with saxagliptin 2-step and 1-step titration versus placebo (P<0.001) | Mean decreases from baseline to week 12 were significant with saxagliptin 2-step and 1-step titration versus placebo (P<0.001) |
| Saxagliptin           | 102                   | 48/54                                                                      |                                                                            |                                                                            |
| Saxagliptin           | 284                   | 160/124                                                                   |                                                                            |                                                                            |

**Notes:**
- *P<0.0001*
- *P<0.001*
- *P<0.002*
- *P<0.007*
- *P<0.01*
- *P<0.05*
- *P<0.025*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
- *P<0.05*
- *P<0.01*
- *P<0.001*
| Drug       | Dose (mg) | Mean Decreases from Baseline to Day 14 (4-Hour PPG) | Mean Decreases from Baseline to Week 12 (PPG AUC) |
|------------|-----------|----------------------------------------------------|--------------------------------------------------|
| Alogliptin | 25, 100, or 400 mg qd | Significant with all three doses of alogliptin versus placebo after breakfast, lunch, and dinner (all P ≤ 0.017) | Increase in AUC significant for all four doses of alogliptin versus placebo and for the two highest doses versus voglibose (P-values not specified) |
| Alogliptin | 62.5, 12.5, 25, or 50 mg qd | Matching placebo | Matching placebo |
| Voglibose 0.2 mg tid | | | |
| Matching placebo | | | |
| Matching placebo | | | |
| Matching placebo | | | |
| Linagliptin | 5 mg qd | Increase in PPG AUC significant for all four doses of alogliptin versus placebo and for the two highest doses versus voglibose (P-values not specified) | Increase in PPG AUC significant for all four doses of alogliptin versus placebo and for the two highest doses versus voglibose (P-values not specified) |
| Linagliptin | 2.5, 5, or 10 mg qd | Matching placebo | Matching placebo |
| Voglibose 0.2 mg tid | | | |
| Voglibose 0.2 mg tid | | | |
| Matching placebo | | | |
| Dutogliptin | 200 mg or 400 mg qd | Increase in PPG AUC significant with both doses of dutogliptin versus placebo (both P ≤ 0.032) | Increase in PPG AUC significant with both doses of dutogliptin versus placebo (both P ≤ 0.032) |
| Dutogliptin | 200 mg or 400 mg qd | Matching placebo | Matching placebo |

**Notes:**
- Average incremental increase, calculated as the AUC over the fasting value from time 0 to 5 hours.
- Mean age (range), years.
- Median age (range), years.

**Abbreviations:**
- AUC, area under the curve; BID, twice daily; CI, confidence interval; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; PPG, postprandial glucose; PPG-excursion; qd, once daily; SD, standard deviation; tid, three times daily.

---

**Gastrointestinal side effects are relatively common with incretin-based therapies.** Recent clinical trial publications have described the activity of exenatide in reducing PPG as monotherapy (Table 3) or as add-on therapy to metformin (Table 4). Pooled data from clinical trials of exenatide as add-on therapy with metformin and/or sulfonylurea show that exenatide injected twice daily reduces mean PPG concentrations compared with placebo (Table 5).
Table 2 PPG outcomes as add-on to metformin: selected trials published from 2008 to October 2012

| Drug | Baseline demographics | Treatments | PPG outcome |
|------|-----------------------|------------|-------------|
| | Patients, n | Male/female, n/n | Mean age (SD), years | | |
| **GLP-1 analogs** | | | | |
| Exenatide<sup>40</sup> | 234 | 48%/52% | 55 (9) | • Exenatide 5 μg bid for 4 weeks and 10 μg bid for 12 weeks | Mean decrease in morning, midday, and evening PPG at week 16 significant for exenatide plus metformin versus placebo plus metformin (P<0.001) |
| | | | | • Matching placebo | |
| | | | | • Exenatide 5 μg bid for 4 weeks and then 10 μg bid, with titration up to 20 μg tid if needed | Mean decrease in PPG AUC at weeks 26 and 52 significant for exenatide plus metformin versus insulin glargine plus metformin (P<0.001) |
| | | | | • Insulin glargine 10 U qd followed by self-adjusted dosing | |
| Exenatide<sup>41,62</sup> | • Exenatide, 205 | 55%/45% | • 59 (9) | • Exenatide 5 μg bid for 1 week and 10 μg bid for 1 week | Mean morning, midday, and evening 2-hour PPG at week 2 significantly lower for exenatide plus metformin versus placebo plus metformin (P<0.001) |
| | • Insulin glargine, 209 | 55%/45% | • 57 (10) | • Matching placebo | |
| Exenatide<sup>43</sup> | 30 | 11/19 | 53 (11) | • Lixisenatide 5, 10, 20, or 30 μg qd or bid | Mean decreases in morning 2-hour PPG at week 13 significant for all doses of lixisenatide plus metformin versus placebo plus metformin (P<0.01 except for lowest dose given qd or bid [P<0.05]) |
| | | | | • Matching placebo | |
| **DPP-4 inhibitors** | | | | |
| Sitagliptin<sup>46</sup> | • Sitagliptin, 248 | 42%/58% | • 58 (9) | • Sitagliptin 100 mg qd | Mean decrease from baseline to year 2 in PPG AUC seen with sitagliptin plus metformin but not glipizide plus metformin |
| | • Glipizide, 256 | 161/95 | • 57 (9) | • Glipizide 5 mg qd | |
| Saxagliptin<sup>47</sup> | 93 | 49/44 | 55 (9) | • Saxagliptin 5 mg qd | Mean decreases from baseline to week 4 in 2-hour and 4-hour PPG (evening meal) significant with saxagliptin plus metformin versus placebo plus metformin (P<0.001) |
| | | | | • Matching placebo | |
| Saxagliptin<sup>113</sup> | • 2.5 mg, 192 | 83/109 | • 55 (10) | • Saxagliptin 2.5, 5, or 10 mg qd | Mean decreases from baseline to week 24 in 2-hour PPG and PPG AUC significant with all doses of saxagliptin plus metformin versus placebo plus metformin (P<0.001) |
| | • 5 mg, 191 | 103/88 | • 55 (10) | • Matching placebo | |
| | • 10 mg, 181 | 95/86 | • 54 (10) | | |
| Saxagliptin<sup>148</sup> | • Saxagliptin + metformin, 138 | 57/81 | • 55 (9) | • Saxagliptin 5 mg + metformin XR 1,500 mg qd | Mean decreases from baseline to week 18 in 2-hour PPG significant with saxagliptin plus metformin XR 1,500 mg versus metformin XR 2,000 mg (P=0.001) |
| | • Metformin, 144 | 73/71 | • 56 (10) | • Metformin XR 2,000 mg qd | |
| Vildagliptin<sup>12,149</sup> | 2,789 | 1,490/1,299 | 57 (9) | • Vildagliptin 50 mg bid | Mean decrease from baseline to year 2 in PPG AUC similar with vildagliptin plus metformin and glimepiride plus metformin |
| Linagliptin<sup>112</sup> | 700 | 379/321 | 57 (10) | • Linagliptin 5 mg qd | Mean decrease from baseline to week 24 in 2-hour PPG levels significant with linagliptin plus metformin versus placebo plus metformin (P<0.0001) |

Abbreviations: AUC, area under the curve; bid, twice daily; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; PPG[e], postprandial glucose [excursion]; qd, once daily; SD, standard deviation; tid, three times daily; XR, extended release.
### Table 3 PPG outcomes as add-on to a sulfonylurea: trials published from 2008 to October 2012

| Drug          | Baseline demographics | Treatments | PPG outcome |
|---------------|-----------------------|------------|-------------|
| GLP-1 analogs |                       |            |             |
| Liraglutide   | 264                   | 169/95     | 60 (10)     |
|               | Male/female, n/n      |            |             |
|               | Mean age (SD), years  |            |             |
|               | Liraglutide 0.6 or 0.9 mg qd | Matching placebo | Mean decreases from baseline to week 24 in PPG AUC significant with both liraglutide doses versus placebo ($P<0.0001$), as add-on to glibenclamide, glicazide, or glimepride |
| DPP-4 inhibitors |                |            |             |
| Saxagliptin   | 115, 116              | 113/135    | 55 (10)     |
|               | 2.5 mg, 248           | 43/42      | 59 (5)      |
|               | 5 mg, 253             | 42/41      | 59 (6)      |
|               | Saxagliptin 2.5 or 5 mg qd | Matching placebo | Mean decreases from baseline to week 24 in 2-hour PPG and PPG AUC significant with saxagliptin plus upptitrated glyburide versus placebo plus upititrated glyburide ($P<0.0001$); updated data at week 76 data were consistent with those at week 24 |
| Vildagliptin   | 85, 83                | 43/42      | 59 (5)      |
|               | Vildagliptin + glimepiride | 58 (5) | Vildagliptin 50 mg bid + glimepiride 2 mg tid |
|               | Vildagliptin + pioglitazone | 59 (6) | Vildagliptin 50 mg bid + pioglitazone 30 mg qd |
|               | 50 mg qd, 132         | 78/54      | 59 (11)     |
|               | 50 mg bid, 132        | 79/53      | 58 (11)     |
|               | Vildagliptin 50 mg qd or bid | Matching placebo | Mean decreases from baseline to week 24 in PPG[E] significant for vildagliptin 50 mg plus glimepiride versus placebo plus glimepiride ($P=0.008$; significance not reached for 100 mg dose versus placebo ($P=0.085$)) |
| DPP-4 inhibitors |                |            |             |
| Sitagliptin   | 322                   | 157/165    | 58 (9)      |
|               | Sitagliptin 100 mg qd | Matching placebo | Mean decrease from baseline to week 24 in 2-hour PPG significant with sitagliptin plus insulin ± metformin versus placebo plus insulin ± metformin ($P<0.0001$) |
| Saxagliptin   | 304                   | 120/184    | 57 (9)      |
|               | Saxagliptin 5 mg qd   | Matching placebo | Mean decrease from baseline to week 24 in 180-minute and 120-minute PPG significant with saxagliptin plus insulin ± metformin versus placebo plus insulin ± metformin (P=0.011 and P=0.016, respectively) |

**Abbreviations:** AUC, area under the curve; bid, twice daily; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; PPG[E], postprandial glucose [excursion]; qd, once daily; SD, standard deviation; tid, three times daily.

### Table 4 PPG outcomes as add-on to insulin: trials published from 2008 to October 2013

| Drug          | Baseline demographics | Treatments | PPG outcome |
|---------------|-----------------------|------------|-------------|
| GLP-1 analogs |                       |            |             |
| Exenatide     | 137                   | 70/67      | 59 (9)      |
|               | Male/female, n/n      |            |             |
|               | Mean age (SD), years  |            |             |
|               | Exenatide 10 μg bid   | Matching placebo | Mean decrease from baseline to week 30 in morning and evening 2-hour PPG significant with exenatide plus insulin glargine versus placebo plus insulin glargine ($P<0.001$); however, no significant difference in midday 2-hour PPG |
| Lixisenatide  | 495                   | 228/267    | 57 (10)     |
|               | Male/female, n/n      |            |             |
|               | Mean age (SD), years  |            |             |
|               | Lixisenatide 20 μg qd | Matching placebo | Mean decrease from baseline to week 24 in 2-hour postbreakfast PPG significant with lixisenatide plus basal insulin ± metformin versus placebo plus basal insulin ± metformin ($P<0.0001$) |
| Lixisenatide  | 154                   | 69/85      | 59 (10)     |
|               | Male/female, n/n      |            |             |
|               | Mean age (SD), years  |            |             |
|               | Lixisenatide 20 μg qd | Matching placebo | Mean decrease from baseline to week 24 in 2-hour PPG significant with lixisenatide plus basal insulin ± sulfonylurea versus placebo plus basal insulin ± sulfonylurea ($P<0.0001$) |
| DPP-4 inhibitors |                |            |             |
| Sitagliptin   | 322                   | 157/165    | 58 (9)      |
|               | Male/female, n/n      |            |             |
|               | Mean age (SD), years  |            |             |
|               | Sitagliptin 100 mg qd | Matching placebo | Mean decrease from baseline to week 24 in 2-hour PPG significant with sitagliptin plus insulin ± metformin versus placebo plus insulin ± metformin ($P<0.001$) |
| Saxagliptin   | 304                   | 120/184    | 57 (9)      |
|               | Male/female, n/n      |            |             |
|               | Mean age (SD), years  |            |             |
|               | Saxagliptin 5 mg qd   | Matching placebo | Mean decrease from baseline to week 24 in 180-minute and 120-minute PPG significant with saxagliptin plus insulin ± metformin versus placebo plus insulin ± metformin (P=0.011 and P=0.016, respectively) |

**Abbreviations:** AUC, area under the curve; bid, twice daily; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; PPG, postprandial glucose; qd, once daily; SD, standard deviation; tid, three times daily.
(129 patients, 77 male/52 female; mean age 56±11 years) was associated with significantly greater reductions in HbA₁c compared with exenatide twice daily (123 patients, 68 male/55 female; mean age 55±10 years) over 24 weeks of treatment (−1.6% versus −0.9%, \(P<0.0001\)); however, PPG was not measured in DURATION-5. Overall, there were six DURATION studies that all had similar outcomes, showing that exenatide once weekly resulted in significant improvements in glycemic control with no increased risk of hypoglycemia.65–70

Liraglutide is a nonprandial (long-acting) GLP-1 receptor agonist showing 97% sequence homology with human GLP-1,71 with recent clinical trial data supporting its efficacy in reducing PPG as monotherapy (Table 172–74) or as add-on therapy to a sulfonylurea (Table 375,76). A study by Garber et al (Liraglutide versus glimepiride monotherapy for type 2 diabetes [LEAD-3]) comparing liraglutide 1.2 mg (251 patients, 117 male/134 female; mean age 54±11 years) and liraglutide 1.8 mg (247 patients, 121 male/126 female; mean age 52±11 years) versus glimepiride 8.0 mg (248 patients, 133 male/115 female; mean age 53±11 years) monotherapy in 746 patients with type 2 diabetes who were either drug-naïve or treated with oral antidiabetic drugs found that liraglutide resulted in significantly greater reductions in mean HbA₁c (liraglutide 1.2 mg, 0.84% [\(P<0.0001\)]; liraglutide 1.8 mg, 1.14% [\(P=0.0014\)]) compared with glimepiride 8.0 mg (0.51%).74 Additionally, compared with glimepiride, patients treated with liraglutide had significantly greater reductions in FPG (1.2 mg, \(P=0.027\); 1.8 mg, \(P=0.0001\)) and PPG (1.8 mg, \(P=0.0038\)) levels.74 In a study by Buse et al (LEAD-6) evaluating 464 patients with type 2 diabetes who were inadequately controlled with metformin, sulfonylurea, or a combination of the two, the addition of once-daily liraglutide (233 patients, 114 male/119 female; mean age 56±10 years) resulted in significantly greater reductions in mean HbA₁c (−1.12% versus −0.79%; \(P<0.0001\)) and mean FPG (−1.61 mmol/L versus −0.60 mmol/L; \(P<0.0001\)) than the addition of twice-daily exenatide (231 patients, 127 male/104 female; mean age 57±11 years).76 In contrast, treatment with twice-daily exenatide resulted in significantly greater reductions in mean PPG after breakfast and dinner (\(P=0.0005\) for both comparisons).76 Similar to exenatide, the most common adverse events associated with liraglutide are gastrointestinal disorders, including nausea, vomiting, and diarrhea.71,76 Liraglutide treatment was associated with increased rates of thyroid medullary carcinoma in preclinical toxicity studies,77 and liraglutide therapy is contraindicated in patients with a personal or family history of thyroid medullary cancer.54

Several additional GLP-1 analogs are in development, including lixisenatide and albiglutide, which are discussed below. The GLP-1 analog taspoglutide, for which clinical development was discontinued in 2010, will not be discussed.

### Lixisenatide

Lixisenatide once daily is a highly potent and selective prandial (short-acting) GLP-1 receptor agonist that is currently in development for the treatment of type 2 diabetes, and was recently (February 2013) granted marketing authorization by the European Medicines Agency. In preclinical studies, the binding affinity of lixisenatide for the GLP-1 receptor was approximately four times stronger than that of human GLP-1. In preclinical pharmacology studies, lixisenatide has been shown to: protect pancreatic β-cells from apoptosis; improve glucose-stimulated pancreatic insulin secretion; preserve pancreatic responsiveness, insulin mRNA expression, and β-cell mass; improve oral glucose tolerance; delay gastric emptying; and decrease overall food intake. All of these actions suggest that lixisenatide has the potential to markedly improve glucose homeostasis and slow the progression of type 2 diabetes.78

A dose-ranging study evaluated the efficacy and safety of lixisenatide as add-on therapy in 542 patients with type 2 diabetes inadequately controlled with metformin; once-daily lixisenatide significantly reduced mean 2-hour PPG compared with placebo (\(P<0.05\) for all doses tested) over 13 weeks of treatment (Table 2). In addition, patients treated with lixisenatide 20 μg once daily experienced significant reductions from baseline in body weight, and more than two thirds of patients achieved the target HbA₁c level of <7%, with an optimal risk-benefit ratio versus other doses and regimens.79

The GetGoal Phase III clinical development program has evaluated the efficacy and safety of once-daily lixisenatide across the disease spectrum: as monotherapy in patients insufficiently controlled despite diet and exercise (GetGoal-Mono), to those treated with one or two other oral antidiabetic agents (GetGoal-M, GetGoal-S, and GetGoal-P), to the insulin-naïve patients (GetGoal Duo-1), as well as in patients on an established insulin regimen (GetGoal-L and GetGoal-L-Asia). In this program, lixisenatide has consistently demonstrated significant reductions in HbA₁c (by 0.32%–0.88% versus placebo) and PPG levels, and has been shown to have a beneficial effect on weight as well as tolerability profiles.
commonly characterized by adverse events of mild transient nausea and vomiting.\textsuperscript{80-87} As monotherapy in the GetGoal-Mono study, both HbA\textsubscript{1c} and 2-hour PPG levels decreased significantly (\( P<0.001 \)) over the 12-week course of treatment with lixisenatide compared with placebo (Table 1), and significant improvements in FPG compared with placebo were observed for both doses of lixisenatide (two-step titration of 10/15/20 \( \mu \)g once daily and one-step titration of 10/20 \( \mu \)g once daily).\textsuperscript{88} Similar improvements in HbA\textsubscript{1c} and PPG levels were demonstrated for lixisenatide in patients whose type 2 diabetes was insufficiently controlled while on metformin in the GetGoal-L study and on a sulfonylurea with or without metformin in the GetGoal-S study.\textsuperscript{86,87} In the GetGoal-P study, addition of once-daily lixisenatide in patients with type 2 diabetes poorly controlled with pioglitazone with or without metformin resulted in significantly greater reductions in HbA\textsubscript{1c} and a significantly higher percentage of patients achieved an HbA\textsubscript{1c} <7.0\% (52\% versus 26\%; \( P<0.0001 \)).\textsuperscript{81}

Evaluation of lixisenatide as add-on in patients sub-optimally controlled on basal insulin with or without metformin in the GetGoal-L study and with sulfonylurea in the GetGoal-L-Asia study showed that lixisenatide significantly reduced HbA\textsubscript{1c} and 2-hour PPG compared with placebo (Table 4). Lixisenatide also had favorable effects on body weight (least-squares mean difference versus placebo for GetGoal-L, \(-1.28 \text{ kg [95% CI: } -1.36 \text{ to } -1.20 \text{ kg}] \) and for GetGoal-L-Asia, \(-0.43 \text{ kg [95% CI: } -0.56 \text{ to } -0.30 \text{ kg}] \)) and for GetGoal-M (mean \(-0.66 \text{ kg [95% CI: } -0.81 \text{ to } -0.50 \text{ kg}] \) versus placebo).\textsuperscript{89,90} Similarly, in the GetGoal-Duo 1 study (898 patients, 466 male/432 female; mean age 56±10 years), once-daily lixisenatide added to consistently titrated insulin glargine plus metformin with or without a thiazolidinedione significantly improved HbA\textsubscript{1c} and 2-hour PPG compared with placebo, with significant weight reduction (least-squares mean difference versus placebo, \(-0.89 \text{ kg; [95% CI: } -1.00 \text{ to } -0.78 \text{ kg}] \) and a significantly higher percentage of patients achieving HbA\textsubscript{1c} <7.0\% (lixisenatide, 56\%; placebo, 39\%; \( P=0.0001 \)).\textsuperscript{92}

**Albiglutide**

Albiglutide is a GLP-1 receptor agonist that consists of a DPP-4-resistant GLP-1 dimer fused to recombinant human albumin.\textsuperscript{88} Albiglutide has a half-life of approximately 5 days, which may allow for weekly or less frequent dosing.\textsuperscript{89} Albiglutide does not cross the blood-brain barrier in a GLP-1 receptor-independent manner as does native GLP-1\textsuperscript{90,91} and the smaller GLP-1 analogs exenatide\textsuperscript{92} and liraglutide,\textsuperscript{93} which may improve its gastrointestinal tolerability.\textsuperscript{89,94} In a randomized, single-blind, dose-escalation study in patients with type 2 diabetes (\( n=54 \)), albiglutide consistently reduced FPG and PPG concentrations in a dose-dependent manner (Table 1). The safety profile of albiglutide was similar to that of placebo. Headache and nausea were the most frequently reported adverse events.\textsuperscript{88} In a separate randomized, double-blind, placebo-controlled, and active-controlled study, significant reductions were observed in mean HbA\textsubscript{1c} levels compared with placebo in patients who received albiglutide 30 mg weekly, 50 mg biweekly, or 100 mg monthly (all \( P<0.05 \)); reductions in mean HbA\textsubscript{1c} levels with these doses of albiglutide were approximately 25\%–30\% greater than those observed with twice-daily exenatide.\textsuperscript{89} In addition, patients who received albiglutide lost an average of 1.1–1.6 kg; weight loss on albiglutide treatment was numerically higher than on placebo (average weight loss, 0.7 kg) but numerically lower than on exenatide treatment (average weight loss, 2.4 kg).\textsuperscript{99}

Results from the HARMONY 6 and 7 trials for albiglutide were recently reported.\textsuperscript{95-97} In HARMONY 6, albiglutide demonstrated noninferiority to preprandial insulin lispro as add-on treatment to insulin glargine, with clinically significant reductions in HbA\textsubscript{1c} from baseline (\(-0.82\% \) versus \(-0.66\% \)) concomitant with weight loss compared with baseline (\(-0.73 \text{ kg versus } +0.81 \text{ kg} \) after 26 weeks of treatment.\textsuperscript{95} Patients who completed 52 weeks of treatment in HARMONY 6 had further reductions in HbA\textsubscript{1c} from baseline (\(-1.01\% \) versus \(-0.84\% \)), with sustained weight changes.\textsuperscript{97} In the 32-week HARMONY 7 trial, albiglutide demonstrated a significant reduction in HbA\textsubscript{1c} from baseline but did not meet the endpoint of noninferiority compared with liraglutide (\(-0.78\% \) versus \(-0.99\% \)).\textsuperscript{96} Albiglutide also resulted in a smaller difference in weight loss (\(-0.64 \text{ kg versus } -2.2 \text{ kg} \), but with fewer gastrointestinal adverse events.

**Comparison of the GLP-1 analogs**

The prandial GLP-1 analogs (twice-daily exenatide and once-daily lixisenatide) lower HbA\textsubscript{1c} primarily by targeting PPG, while the nonprandial GLP-1 analogs (liraglutide, exenatide LAR, and albiglutide) primarily target FPG.\textsuperscript{85,76,84,87,89,98} Exenatide LAR 2 mg once weekly had a greater effect on FPG (least-squares mean [standard error] for exenatide LAR, \(-2.3 \text{ [0.2] mmol/L; for exenatide twice daily, } -1.4 \text{ [0.2] mmol/L} \) and a lesser effect on PPG (least-squares mean [standard error] for exenatide LAR, \(-5.3 \text{ [0.5] mmol/L; for exenatide twice daily, } -6.9 \text{ mmol/L} \) compared with exenatide 10 \( \mu \)g twice daily after 30 weeks of treatment.\textsuperscript{83} In a 26-week, direct-comparison trial with exenatide and liraglutide, exenatide had a higher effect on PPG reduction (estimated...
For DPP-4 inhibitors to be effective, some residual insulin secretion must remain. The once-daily prandial lixisenatide, which primarily targets PPG, has consistently provided significant improvements in glycemic control as well as reductions in body weight when administered as monotherapy, as add-on treatment to metformin or sulfonylurea ± metformin, and as add-on therapy to insulin ± metformin. Results from one study showed that the glycemic effects of lixisenatide were superior to those of liraglutide. In this study, 2-hour PPG levels <140 mg/dL were reported by a higher percentage of patients who received lixisenatide (69%) than liraglutide (29%), and lixisenatide treatment resulted in a significantly greater decrease in postprandial glucagon than liraglutide (P=0.032). Further, efficacy results from the GetGoal-L and GetGoal-Duo studies support the clinical rationale for combination of lixisenatide with basal insulin to improve glycemic control by reducing both PPG and FPG.

The gastric emptying effect of GLP-1, which lowers PPG, has been shown to decrease after chronic administration (tachyphylaxis) of intravenous GLP-1 in healthy human subjects. An area that remains to be investigated is whether tachyphylaxis occurs with GLP-1 analogs and if the long-term efficacy in reducing PPG varies for different GLP-1 analogs due to different dosing regimens and/or duration of action. If confirmed, the tachyphylaxis hypothesis could partially explain the differential effects of GLP-1 receptor agonists on FPG and PPG.

**DPP-4 inhibitors**

DPP-4 inhibitors decrease the metabolism of GLP-1 and GIP through inhibition of the DPP-4 enzyme, which under normal physiologic conditions cleaves the two end-terminal amino acids of GLP-1 and GIP to rapidly inactivate these hormones. By prolonging the action of GLP-1, DPP-4 inhibitors improve both α-cell and β-cell responsiveness to glucose. Inhibition of DPP-4 increases prandial insulin secretion and suppresses glucagon secretion, thereby decreasing hepatic glucose production and improving peripheral glucose uptake, which decreases PPG in patients with type 2 diabetes. For DPP-4 inhibitors to be effective, some residual insulin secretion must remain. The DPP-4 inhibitors that are currently approved or in development for the treatment of type 2 diabetes all have convenient oral dosing, along with a low risk of hypoglycemia and weight gain. Similar to GLP-1 agonists, the ADA/EASD 2012 position statement on diabetes treatment recommendations includes DPP-4 inhibitors as an option for add-on therapy in patients who fail to reach their glycemic targets with metformin.

Three DPP-4 inhibitors, sitagliptin (Januvia®; Merck and Co, Inc, Whitehouse Station, NJ, USA), saxagliptin (Onglyza®; Bristol-Myers Squibb, New York, NY, USA), and linagliptin (Tradjenta®; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, and Eli Lilly and Company, Indianapolis, IN, USA) are approved in the US as oral antidiabetic therapies; other agents in clinical development are discussed individually below.

Linagliptin, the newest of these agents, is a potent and selective xanthine-based DPP-4 inhibitor with a long duration of action; more than 80% inhibition of DPP-4 is still present 24 hours after dosing. Across a number of recently published placebo-controlled trials, the PPG-lowering effects of each of the three approved agents as monotherapy (Table 1) or as add-on therapy to metformin (Table 2) have been described, with additional data available for saxagliptin as add-on therapy to a sulfonylurea or metformin (Table 3) and insulin with or without metformin (Table 4). Sitagliptin as add-on therapy to insulin or the combination of insulin plus metformin (Table 4) and linagliptin as add-on therapy to basal insulin. Sitagliptin, saxagliptin, and linagliptin have neutral effects on weight, do not cause hypoglycemia (although risk is increased when used as add-on therapy to a sulfonylurea or [for sitagliptin] with insulin), and are not associated with the gastrointestinal adverse event profiles characteristic of the GLP-1 receptor agonists. However, there have been postmarketing reports of pancreatitis and severe allergic or hypersensitivity reactions with both sitagliptin and saxagliptin. While results of recent clinical trials involving DPP-4 inhibitors indicate that they effectively reduce HbA1c levels and improve pancreatic β-cell function, long-term data assessing the sustainability of glycemic control provided by these agents are not yet available.

**Vildagliptin**

Vildagliptin (Galvus®; Novartis AG, Basel, Switzerland) is approved in Europe and in several other countries worldwide for the treatment of type 2 diabetes; however, the FDA has requested additional cardiovascular safety data in order for vildagliptin to gain approval in the US. In June 2008, Novartis indicated that resubmission of a New Drug Application was not planned in order to meet FDA requirements.
Despite the fact that vildagliptin will probably not be marketed in the US, recently published clinical trial results indicate that vildagliptin is well tolerated and effectively reduces PPG levels as add-on therapy to metformin (Table 2),\textsuperscript{122} a sulfonylurea (Table 3),\textsuperscript{123,124} or insulin with or without metformin.\textsuperscript{125}

**Alogliptin**

Alogliptin is a potent and highly selective DPP-4 inhibitor currently being developed by Takeda Pharmaceutical Company Ltd (Osaka, Japan). Takeda submitted a New Drug Application for alogliptin to the FDA in January 2008; however, in June 2009, the FDA requested additional cardiovascular safety data for alogliptin. A clinical cardiovascular outcomes trial of alogliptin is currently recruiting patients (ClinicalTrials.gov identifier NCT00968708).\textsuperscript{103}

Compared with sitagliptin, saxagliptin, and vildagliptin, alogliptin has higher selectivity for DPP-4 versus the dipeptidases DPP-8 and DPP-9. This is notable because inhibition of DPP-8 and DPP-9 has been shown to decrease human T-cell activation in vitro and cause multiple organ toxicity in dogs and rats.\textsuperscript{103}

In a randomized, placebo-controlled study, significant decreases were observed in mean 4-hour PPG levels over 14 days of treatment with three different doses of once-daily alogliptin compared with placebo (Table 1). Alogliptin was well tolerated; the most commonly reported adverse events were headache, dizziness, and constipation.\textsuperscript{128} In a separate 12-week, randomized, double-blind, placebo-controlled, and active-controlled study of once-daily alogliptin 6.25 mg, 12.5 mg, 25 mg, or 50 mg, significantly larger decreases in PPG (based on the area under the concentration-time curve from 0 to 2 hours [AUC\textsubscript{0–2h}]) were observed from baseline to week 12 with all four doses of alogliptin compared with placebo (Table 1).\textsuperscript{127}

**Dutogliptin**

Dutogliptin is a potent and selective DPP-4 inhibitor with high solubility in water and low cell permeability. Dutogliptin does not bind extensively with plasma proteins. Maximum absorption of dutogliptin occurs within 3–4 hours of dosing, and dutogliptin has a half-life of 10–13 hours. In a randomized, placebo-controlled study, reductions in 2-hour PPG were significantly greater with once-daily dutogliptin than with placebo (Table 1). Dutogliptin was weight-neutral, with a safety profile similar to that of placebo. Across all treatment groups, the most commonly reported adverse events in this study were urinary tract infection (4.3%), diarrhea (3.6%), upper respiratory tract infection (3.6%), and headache (3.3%).\textsuperscript{128}

**Comparison of DPP-4 inhibitors and GLP-1 receptor agonists**

The DPP-4 inhibitor and GLP-1 receptor agonist classes differ in their food and digestive effects and other clinical aspects, including the extent to which they reduce HbA\textsubscript{1c}, PPG, and body weight (Figure 3).\textsuperscript{129} GLP-1 agonists have shown a greater effect in lowering HbA\textsubscript{1c} (–0.4% to –1.9%) compared with DPP-4 inhibitors (–0.4% to –0.9%\textsuperscript{65,129}). The clinically relevant impact of such differences on the relative PPG-lowering effects of DPP-4 inhibitors versus GLP-1 receptor agonists has not been extensively addressed. A double-blind, randomized, double-dummy, crossover study\textsuperscript{130} compared the effects of the GLP-1 analog exenatide (5 μg twice daily during week 1, 10 μg twice daily during week 2) versus the DPP-4 inhibitor sitagliptin (100 mg every morning for 2 weeks) on 2-hour PPG, insulin and glucagon secretion, gastric emptying, and caloric intake in patients with type 2 diabetes (n=61, 28 male/33 female; mean age 54±9 years). Although this study was limited by a 2-week duration of exposure to each medication, the results showed that the GLP-1 analog reduced 2-hour PPG concentration significantly more than the DPP-4 inhibitor (2-hour PPG concentration at week 2, 133±6 mg/dL versus 208±6 mg/dL; P<0.0001). Acute β-cell function, assessed using the insulogenic index and insulin secretion rate, improved significantly more following treatment with the GLP-1 analog compared with the DPP-4 inhibitor. In addition, treatment with the GLP-1 receptor agonist was associated with significantly greater reductions in postprandial glucagon secretion, postprandial triglycerides, and caloric intake compared with the DPP-4 inhibitor. Gastric emptying was also delayed to a greater extent with the GLP-1 receptor agonist compared with the DPP-4 inhibitor.\textsuperscript{130}

Modest improvements in cardiovascular risk factors such as blood pressure and lipid levels have been reported in patients treated with either DPP-4 inhibitors or GLP-1 receptor agonists.\textsuperscript{131} Recently published pooled analyses of randomized controlled trials in patients with type 2 diabetes mellitus have confirmed a cardioprotective effect for two GLP-1 agonists, ie, exenatide 10 μg twice daily\textsuperscript{132} and exenatide once weekly.\textsuperscript{133} In both analyses, treatment with either agent resulted in improved blood pressure and lipid profiles, regardless of baseline age, sex, race, duration of diabetes, or body mass index. Meta-analyses of clinical trial data for the DPP-4 inhibitors saxagliptin and linagliptin
suggest that these drugs are also associated with a decreased cardiovascular risk. Cardiovascular outcomes trials are needed to confirm whether treatment with DPP-4 inhibitors or GLP-1 receptor agonists will result in long-term reductions in cardiovascular risk and improved patient outcomes. In addition, to satisfy criteria outlined in the December 2008 “Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes,” the FDA has requested additional cardiovascular safety data as part of the clinical development program for any new type 2 antidiabetic therapy.

Acute pancreatitis has been reported in patients treated with exenatide, liraglutide, and sitagliptin, raising the concern that there may be a mechanism-based association between pancreatitis and incretin therapies. In a retrospective analysis of the FDA’s voluntary adverse event reporting database, pancreatitis was found to be reported over six-fold more frequently for either sitagliptin or exenatide therapy compared with four other diabetes therapies (rosiglitazone, nateglinide, repaglinide, and glipizide). A broader retrospective analysis of PubMed articles performed by Drucker et al concludes that preclinical studies do not support an increase in the rate or severity of pancreatitis with exenatide, liraglutide, or sitagliptin treatment and that, overall, retrospective case studies do not link incretin therapies to pancreatitis. In two retrospective analyses of different health insurance claims databases, the risks of pancreatitis for patients who initiated exenatide or sitagliptin were found to be comparable with those for patients who initiated either metformin or glyburide and for patients who initiated either a sulfonylurea, biguanide, or thiazolidinedione. Longer-term, prospective, controlled trials are needed to assess whether a clear association exists between pancreatitis and these incretin therapies.

Warnings of the high incidences of acute pancreatitis are included in the most current prescribing information for exenatide twice daily and exenatide once weekly states that other antidiabetic therapies should be considered in patients with a history of pancreatitis.

The risk of thyroid cancer is another safety concern that has been raised with incretin therapies. In preclinical studies of liraglutide, an increase in the formation of thyroid tumors

---

**Figure 3** Comparison of GLP-1 agonists and DPP-4 inhibitors.

| GLP-1R agonist | DPP-4 inhibitor |
|----------------|-----------------|
| **Glycemic effects** | **Glycemic effects** |
| ↑ Insulin secretion (glucose-dependent) | ↑ Insulin secretion (glucose-dependent) |
| ↓ Glucagon secretion (glucose-dependent) | ↓ Glucagon secretion (glucose-dependent) |
| **Food and digestive effects** | **Food and digestive effects** |
| ↑ Satiety | None |
| ↓ Caloric intake | |
| ↓ Gastric emptying rate | |
| **Effects as monotherapy** | **Effects as monotherapy** |
| HBA₁c level | ↓ 0.4%–1.5% |
| Weight | ↓ 2.0–4.3 kg |
| Hypoglycemia | Low risk |
| **Most common adverse effects** | **Most common adverse effects** |
| Transient GI events (eg, nausea) | Nasopharyngitis, headache |

---

GLP-1R agonist

- Subcutaneous injection
- Resists degradation by DPP-4 enzyme
- Pharmacologic level of GLP-1R agonist

- **Glycemic effects**
  - ↑ Insulin secretion (glucose-dependent)
  - ↓ Glucagon secretion (glucose-dependent)
- **Food and digestive effects**
  - ↑ Satiety
  - ↓ Caloric intake
  - ↓ Gastric emptying rate
- **Effects as monotherapy**
  - HBA₁c level: ↓ 0.4%–1.5%
  - Weight: ↓ 2.0–4.3 kg
  - Hypoglycemia: Low risk
- **Most common adverse effects**: Transient GI events (eg, nausea)

- **DPP-4 inhibitor**
- Oral ingestion
- Inhibits DPP-4 enzyme
- Extends elimination half-life of endogenous GIP, GLP-1 (physiologic level)

- **Glycemic effects**
  - ↑ Insulin secretion (glucose-dependent)
  - ↓ Glucagon secretion (glucose-dependent)
- **Food and digestive effects**: None
- **Effects as monotherapy**
  - HBA₁c level: ↓ 0.4%–0.9%
  - Weight: ↓ 0.2–0.9 kg
  - Hypoglycemia: Low risk
- **Most common adverse effects**: Nasopharyngitis, headache

---
was observed in animal models. A retrospective analysis of the FDA’s adverse event reporting database examined the frequency of reported adverse events of thyroid cancer with two other incretin therapies, exenatide and sitagliptin, compared with rosiglitazone. Thyroid cancer was reported significantly more often in the exenatide group compared with the rosiglitazone group (odds ratio 4.73; \( P=4\times10^{-3} \)) but not in the sitagliptin group (odds ratio 1.48; \( P=0.65 \)). As with the risk of pancreatitis, further studies assessing the risk of thyroid cancer and its association with incretin therapies are warranted.

**Conclusion**

Current treatment guidelines for type 2 diabetes mellitus emphasize the importance of controlling postprandial hyperglycemia to optimize glycemic control,\(^{50,51}\) which may result in a lower risk of cardiovascular morbidity and mortality. GLP-1 receptor agonists and DPP-4 inhibitors both reduce postprandial hyperglycemia and may be particularly beneficial for patients early in the progression of diabetes. Results of recent clinical studies suggest that GLP-1 receptor agonists may provide greater benefit than DPP-4 inhibitors in this regard. Both GLP-1 receptor agonists and DPP-4 inhibitors could become a valuable alternative to rapid-acting insulins, by helping to optimize glycemic control in patients unable to achieve HbA\(_{1c} \) goals with basal insulin, with the added benefits of weight loss and a low risk of hypoglycemia.

**Disclosure**

The author declares no research funding by pharmaceutical companies, but serves on advisory boards or speaks for sanofi-aventis US LLC, Boehringer Ingelheim GmbH, Eli Lilly and Company, Bristol-Myers Squibb Company, Johnson & Johnson, and Merck and Co, Inc. Editorial support for the writing of this paper was provided by Nancy Bella of MedErgy, and was funded by sanofi-aventis US LLC. The author was not compensated and retained full editorial control over the content of the manuscript.

**References**

1. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. *Endocr Rev*. 1998;19(4):491–503.
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. *Diabetologia*. 2003;46(1):3–19.
3. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and treatment. *Lancet*. 2008;371(9631):2153–2156.
4. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. *Arch Intern Med*. 2003;163(11):1306–1316.
5. Peter R, Okoseime OE, Rees A, Owens DR. Postprandial glucose – a potential therapeutic target to reduce cardiovascular mortality. *Curr Vasc Pharmacol*. 2009;7(1):68–74.
6. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. *Diabetes Care*. 2007;30(2):263–269.
7. Tibaldi J. Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes. *South Med J*. 2009;102(1):60–66.
8. American Diabetes Association. Standards of medical care in diabetes – 2011. *Diabetes Care*. 2011;34 Suppl 1:S11–S61.
9. Woerle HJ, Neumann C, Zech S, et al. Impact of fasting and postprandial glycaemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycaemia to achieve target HbA\(_{1c} \) levels. *Diabetes Res Clin Pract*. 2007;77(2):280–285.
10. International Diabetes Federation. IDF guideline for management of postmeal glucose. Available from: http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf. Accessed October 26, 2012.
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. *Diabetes Care*. 1999;22(2):233–240.
12. Lin HJ, Lee BC, Ho YL, et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. *Diabetes Care*. 2009;32(9):1721–1726.
13. Gallwitz B. Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. *Diabetes Care*. 2009;32 Suppl 2:S322–S325.
14. Ceriello A, Bortolotti N, Motz E, et al. Meal-generated oxidative stress in type 2 diabetic patients. *Diabetes Care*. 1998;21(9):1529–1533.
15. Ceriello A, Bortolotti N, Motz E, et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. *Metabolism*. 1999;48(12):1503–1508.
16. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hyperglycemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. *Circulation*. 2002;106(10):1211–1218.
17. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2012;35(6):1364–1379.
18. International Diabetes Federation. IDF guidelines for management of postmeal glucose in patients with diabetes. Available from: http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf. Accessed June 6, 2013.
19. Rizzo M, Rizvi AA, Spinias GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. *Expert Opin Investig Drugs*. 2009;18(10):1495–1503.
20. Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. *Am J Physiol Endocrinol Metab*. 2004;287(6):E1049–E1056.
21. Mitra A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. *N Engl J Med*. 1992;326(1):22–29.
22. Woerle HJ, Szoke E, Meyer C, et al. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. *Am J Physiol Endocrinol Metab*. 2006;290(1):E67–E77.
23. Gerich JE. Postprandial hyperglycemia and cardiovascular disease. *Endocr Pract*. 2006;12 Suppl 1:47–51.
24. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA\(_{1c} \). *Diabetes Care*. 2003;26(3):881–885.
25. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of $A_1c$ levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508–2514.

26. van Haefen TW, Pimenta W, Mitraoka A, et al. Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycermia. Metabolism. 2000;49(10):1318–1325.

27. Ceriello A. 25 years of progress in type 2 diabetes. Medicographia. 2011;33:29–34.

28. Ceriello A. Does postprandial blood glucose matter and why? Endocrinol Nutr. 2009;56 Suppl 4:8–11.

29. Noden K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.

30. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011;34 Suppl 2: S120–S127.

31. Deffronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270–1287.

32. Ceriello A, Cavarape A, Martellini L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med. 2004;21(2):171–175.

33. Esposito K, Giugliano D, Nappo F, Marfella R; for the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid athroscerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214–219.

34. Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide (A-4166). Diabetes Care. 2001;24(7):1221–1225.

35. Raz I, Wilson PW, Strojec K, et al. Effects of prandial versus fasting glycaemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32(3):381–386.

36. Ceriello A. Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer? Diabetes Care. 2009;32(3):521–522.

37. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.Curr Med Res Opin. 2007;23(4):905–917.

38. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes—a comprehensive review. Diabetes Technol Ther. 2010;12(1):11–24.

39. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Am J Physiol Endocrinol Metab. 2009;296(4):E223–E236.

40. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc. (2003). 2009;49 Suppl 1:S16–S29.

41. Vollmer K, Gardiwal H, Menge BA, et al. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab. 2009;94(4):1379–1385.

42. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165.

43. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149–5158.

44. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36(11–12):804–810.

45. Campbell RK, Cobble ME, Reid TS, Shamali ME. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. J Fam Pract. 2010;59(Suppl 1):S5–S9.

46. Drucker DJ, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.

47. Melloul JK, Hirshberg B, et al. Exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Care. 2010;33(2):223–229.

48. Campbell RK, Cobble ME, Reid TS, Shamali ME. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. J Fam Pract. 2010;59(Suppl 1):S5–S9.

49. Monnier M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909–917.

50. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.

51. McCulloch DK. Management of persistent hyperglycemia in type 2 diabetes mellitus. Available from: http://www.uptodate.com/contents/management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus?source=search_result&search=persistent+hyperglycemia+in+type+2+diabetes&selectedTitle=1%20E150. Accessed October 26, 2012.

52. Byetta® (exenatide) injection [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2010.

53. BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2012.

54. Victoza® (liraglutide [RNA origin] injection) [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2012.

55. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010;122(3):71–80.

56. Schwartz EA, Koska J, Mullin MP, Syouro I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212(1):217–222.

57. Cervera A, Wajcberg E, Srinijitkamon A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846–E852.

58. Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123(5):468–479, e9–e17.

59. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460.

60. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin sulphonylurea. Diabetes Res Clin Pract. 2009;83(1):69–76.

61. Brodows RG, Qu Y, Johns D, Kim D, Holcombe JH. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(5):1395–1397.

62. Bunck MC, Corner A, Eliaison B, et al. One-year treatment with exenatide vs insulin glargine: effects on postprandial glycaemia, lipid profiles, and oxidative stress. Atherosclerosis. 2010;212(1):223–229.

63. Schwartz SL, Ratner RE, Kim DD, et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther. 2008;30(5):858–867.

64. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–112.

65. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250.
66. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310.

67. Diamant M, Van GL, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–2243.

68. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly vs sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439.

69. Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011;11:9.

70. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28(6):705–714.

71. Edavalath M, Stephens JW. Lisproglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Prefer Adherence. 2010;4:61–68.

72. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011;28(3):213–226.

73. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycaemia with once-daily liraglutide without hypoglycaemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161–168.

74. Garber A, Henry R, Ratner R, et al. Lisproglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, parallel-blind, double-blind trial. Lancet. 2009;373(9662):473–481.

75. Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(4):341–347.

76. Buse JB, Rosenstock J, Sesti G, et al. Lisproglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.

77. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33(2):428–433.

78. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2–3):58–64.

79. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024–1032.

80. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2499–2506.

81. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013;15(11):1000–1007.

82. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497–2503.
100. Kapitza C, Forst T, Coester HV, Potiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lisixenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. *Diabetes Obes Metab*. 2013;15(7):642–649.

101. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. *Diabetes*. 2011;60(5):1561–1565.

102. Rodbard HW, Jefferger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract*. 2009;15(6):540–559.

103. Ghatak SB, Patel DS, Shanker N, Srivastava A, Deshpande SS, Panchal SJ. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. *Curr Diabetes Rev*. 2010;6(6):410–421.

104. Bock G, Dalla Man C, Micheletto F, et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. *Clin Endocrinol (Oxf)*. 2010;73(2):189–196.

105. Januvia™ [sitagliptin] tablets [package insert]. Whitehouse Station, NJ: Merck and Co Inc; 2012.

106. Onglyza™ [saxagliptin] tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.

107. Tradjenta™ [linagliptin] tablets [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2011.

108. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. *Diabetes Obes Metab*. 2011;13(3):258–267.

109. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. *Curr Med Res Opin*. 2009;25(10):2401–2411.

110. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract*. 2008;79(2):291–298.

111. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. *Endocr J*. 2010;57(5):383–394.

112. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes mellitus. *Endocr J*. 2010;57(5):383–394.

113. Defronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care*. 2009;32(9):1649–1655.

114. Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. *Curr Med Res Opin*. 2010;26(10):2355–2363.

115. Chacra AR, Tan GH, Ravichandran S, List J, Chen R. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. *Diab Vasc Dis Res*. 2011;8(2):150–159.

116. Chacra AR, Tan GH, Apanovicth A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. *Int J Clin Pract*. 2009;63(9):1395–1406.

117. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. *Curr Med Res Opin*. 2012;28(4):513–523.

118. Minervini G, Charbonnel B, Barnett AH, Monyak J, Iqbal N. Efficacy and safety of saxagliptin in combination with insulin in patients with long-standing type 2 diabetes. Abstract presented at the American Diabetes Association 72nd Scientific Sessions, June 8–12, 2012, Philadelphia, PA, 2012.

119. Vilbsoll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab*. 2010;12(2):167–177.

120. Yki-Jarvinen H, Duran-Garcia S, Pinnetti S, et al. Efficacy and safety of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes. Abstract presented at the American Diabetes Association 72nd Scientific Sessions, June 8–12, 2012, Philadelphia, PA, 2012.

121. Viereck C, Boudes P. An analysis of the impact of FDA’s guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. *Contemp Clin Trials*. 2011;32(3):324–332.

122. Ahren B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetes Care*. 2010;33(4):730–732.

123. Merck & Co Inc. 2012.

124. Cureo Pharmaceuticals Inc. 2012.

125. Defronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. *Curr Med Res Opin*. 2008;24(10):2943–2952.

126. Dulaglutide, a GLP-1 receptor agonist and DPP-4 inhibitor. Abstract presented at the American Diabetes Association 72nd Scientific Sessions, June 8–12, 2012, Philadelphia, PA, 2012.

127. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. *Diabetes Care*. 2010;33(3):499–512.

128. Pescck R, Blickensderfer A, Li Y, Brunell S, Anderson P. Exenatide is a long-acting GLP-1 receptor agonist, and safety of saxagliptin in combination with insulin in patients with type 2 diabetes mellitus. Abstract presented at the American Diabetes Association 72nd Scientific Sessions, June 8–12, 2012, Philadelphia, PA, 2012.

129. Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. *Postgrad Med*. 2011;124(4):189–201.

130. Pescck R, Brunell S, Li Y, Hoogwerf BJ, Malone J. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. *Postgrad Med*. 2012;124(4):33–40.

131. Pescck R, Brunell S, Li Y, Hoogwerf BJ, Malone J. Exenatide once weekly for the treatment of type 2 diabetes mellitus: cardiovascular safety. *Postgrad Med*. 2012;124(4):54–61.
135. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus – evaluating cardiovascular risk in new anti-diabetic therapies to treat type 2 diabetes. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/%20Guidances/UCM071627.pdf. Accessed October 26, 2012.

136. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1970–1971.

137. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010;64(7):984–990.

138. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–156.

139. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies – review of the scientific evidence. J Clin Endocrinol Metab. 2011;96(7):2027–2031.

140. DoreDD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–1027.

141. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349–2354.

142. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care. 2010;33(2):453–455.

143. Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049–1058.

144. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28(3):268–275.

145. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(6):542–550.

146. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562–576.

147. Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26(10):2355–2363.

148. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs uptitrating metformin dosage. Diabetes Obes Metab. 2012;14(4):365–371.

149. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–166.